Endothelin-1 (ET-1) is present at high concentrations in
ovarian cancer ascites and is overexpressed in primary and metastatic ovarian
carcinomas. In these
tumors, the presence of ET-1 correlates with
tumor grade, enhanced neovascularization, and with
vascular endothelial growth factor (
VEGF) expression. ET-1 acts as an autocrine factor selectively through ET(A) receptor (ET(A)R), predominantly expressed in ovarian
carcinoma cells resulting in increased
VEGF production and
VEGF-mediated angiogenic effects. Previous results demonstrated that in ovarian
carcinoma cells, activation of the ET-1/ET(A)R axis promotes cell proliferation, neovascularization, and invasion, which are the principal hallmarks of
tumor progression. The present study was designed to investigate the in vitro effects of trans, trans-2(4-methoxydhenyl)-4-(1-3-benzodiazol-5-yl)-1-(dibutylaminocarbonylmethyl)-pyrrolidine-3-carboxylic
acid (
ZD4054), an orally active specific ET(A)R antagonist, on the ET-1-induced mitogenic effect in OVCA 433 and HEY ovarian
carcinoma cell lines secreting ET-1 and expressing ET(A)R and ET(B)R
mRNA. We show that ET(A)R blockade by
ZD4054 inhibits ET-1-induced mitogenic effects, while the ET(B)R antagonist,
BQ 788, is ineffective. In conclusion, our data demonstrate that
ZD4054 is capable in inhibiting the proliferative activity of ET-1, indicating that this specific ET(A)R antagonist may be a potential candidate in developing novel treatment of ovarian
carcinoma.